Pharmacological Treatment of Obesity in Older Adults
Open accessThe DOI matches its Crossref record; 77 of the 79 references it cites were found in a registry or an index.
Abstract
Obesity is a complex health issue with growing prevalence worldwide. It is also becoming more prevalent in the population of older adults (i.e., 65 years of age and older), affecting frequency and severity as well as other comorbidities, quality of life and consequently, life expectancy. In this article we review currently available data on pharmacotherapy of obesity in the population of older adults and its role in obesity management. Even though there is growing evidence, in particular in the general population, of favourable efficacy and safety profiles of glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide, and recently dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide, concise guidelines for older adults are not available to this day. We further discuss specific approaches to frequently represented phenotype of obesity in older adults, in particular sarcopenic obesity and rationale when to treat and how. In older adults with obesity there is a need for more drug trials focusing not only on weight loss, but also on geriatric endpoints including muscle mass preservation, bone quality and favourable fat distribution changes to get enough data for evidence-based recommendation on obesity treatment in this growing sub-population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite.”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AEs are more frequent in older adults compared to young adults, and they are particularly noted to occur during dose escalation [12, 43, 57, 75].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, evidence regarding its use in individuals aged 65 years and older remains limited [12].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [12]
In the citing paper
“These effects were consistent across participants aged ≥ 65 and < 65 years [12, 43].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 2×
“Sarcopenia is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality [16].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“Total lean body mass also decreased in absolute terms; the proportion of lean body mass relative to total body mass increased after treatment with semaglutide [60].”
BackgroundMethodInfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“The ratio of total fat mass to total lean mass decreased more with tirzepatide (from 0.93 at baseline to 0.70 at week 72) compared with placebo (from 0.95 to 0.88) [71].”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Health and economic burden of the projected obesity trends in the USA and the UK
Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L., & Brown, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60814-3 · Cited by 2,692
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 4×
“Meta-analysis [21] of 33 intervention studies lasting 8–24 weeks reported that calorie restriction alone without resistance training leads to the loss of muscle mass and loss of handgrip strength [11, 21].”
BackgroundInfluentialSARC-F: A simple questionnaire to rapidly diagnose sarcopenia
Malmstrom, T. K., & Morley, J. E. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.018 · Cited by 1,319
Overview of Epidemiology and Contribution of Obesity to Cardiovascular Disease
Bastien, M., Poirier, P., Lemieux, I., & Després, J.-P. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2013.10.016 · Cited by 1,125
Research works printed but not linked: 2
- Warren MCL, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B. Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1–5 trials. Diabetologia. 2017;60(Suppl 1):1–608.
- Huecker MR, Smiley A, Saadabadi A. Bupropion. Treasure Island: StatPearls; 2024.
Cited by
The Gut Microbiome in Human Obesity: A Comprehensive Review
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Biomedicines · doi:10.3390/biomedicines13092173 · Cited by 64
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101708 · Cited by 28
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?
Chavez, A. M., Barria, R. C., & León-Sanz, M. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001130 · Cited by 30
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
Metadata
- Authors
- Žižka, O., Haluzík, M., & Jude, E. B.
- Affiliations
- Charles University (CZ)
- Tameside Hospital (GB)
- Corresponding author
- Jude, Edward B.
- ORCID
- Jude, Edward B.
- Venue
- Drugs & Aging
- Published
- 2024-11
- Volume
- 41
- Issue
- 11
- Pages
- 881-896
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- PMC
- PMC11554829
- OpenAlex
- W4404195924
- Cited by
- 23
- References
- 79
- Citations by year
- 2026: 11 · 2025: 12
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 7 d)
- Locations
- Drugs & Aging (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Keywords
- obesity, older adults, pharmacotherapy, GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide, GIP/GLP-1 receptor agonist, sarcopenic obesity, weight loss, muscle mass preservation, bone quality, body fat distribution, drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Humans, Obesity, Anti-Obesity Agents, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Treatment of Obesity in Older Adults. https://app.cochat.ai/papers/10.1007/s40266-024-01150-9
- The paper
- Žižka, O., Haluzík, M., & Jude, E. B. (2024). Pharmacological Treatment of Obesity in Older Adults. Drugs & Aging. https://doi.org/10.1007/s40266-024-01150-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Fig. 1 Sarcopenia definition. (Based on criteria from: Sarcopenia: revised European consensus on definition and diagnosis [16].)](https://figures.cochat.ai/paper-figures/0f13db1d008c49a284c8cd17d4d3d15e/pharmacological-treatment-of-obesity-in-older-adults-figure-1.jpg)
